DEFITELIO (Defibrotide Sodium) Patent Expiration, LOE Window & CMS Spending

DEFITELIO (Defibrotide Sodium) by Jazz Pharmaceuticals: FDA Orange Book core substance LOE 2032-06-22, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJazz Pharmaceuticals
FDA Application & PathwayN208114 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-06-22
Last Listed Patent or Exclusivity Date2032-06-22
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 19.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.